Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06667687 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma
A Phase 1 study of Non-Hodgkin's Lymphoma, sponsored by AbbVie.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 165
- Enrollment target
- 14
- Study locations
NCT06667687 is a Phase 1 study of Non-Hodgkin's Lymphoma that is actively recruiting participants, run by AbbVie. The registered enrollment target is 165 participants, below the 219-participant average among 63 other Non-Hodgkin's Lymphoma trials with a reported enrollment target (25% lower). The trial reports 14 study locations across 13 states.
The verdict
NCT06667687, a Phase 1 study of Non-Hodgkin's Lymphoma, is actively recruiting participants, sponsored by AbbVie.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 165 participants
- Enrollment target
- 14
- Study locations
Study Summary
Non-Hodgkin's lymphoma (NHL) is a cancer that arises from the transformation of normal B and T lymphocytes (white blood cells). The purpose of this study is to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of ABBV-291 in adult participants in relapsed or refractory (R/R) NHL, including but not limited to diffuse large b-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and follicular lymphoma (FL). Adverse events will be assessed. ABBV-291 is an investigational drug being developed for the treatment of NHL. This study will include a dose escalation phase to determine the maximum administered dose (MAD)/Maximum tolerated dose (MTD) of ABBV-291 and a dose expansion/optimization phase to determine the change in disease activity in participants with R/R NHL. Approximately 165 adult participants with multiple NHL subtypes will be enrolled in the study in sites world wide In the dose escalation phase of the study participants will receive escalating Intravenously (IV) infused doses of ABBV-291, until the MAD/MTD is determined. In the dose expansion/optimization phase of the study participants receive IV infused ABBV-291, as part of the approximately 74 month study duration. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, and side effects.
Conditions Studied
Interventions
- DRUG ABBV-291
Study Locations (14)
Other
- The Christie /ID# 267177 - Manchester
- University Hospitals Plymouth NHS Trust /ID# 267174 - Plymouth
North Carolina
- Carolina BioOncology Institute /ID# 265259 - Huntersville
Oregon
- Willamette Valley Cancer Institute and Research Center /ID# 270945 - Eugene
Texas
- Texas Oncology - Central/South Texas /ID# 270946 - Austin
Utah
- START Mountain Region /ID# 267592 - West Valley City
Virginia
- Virginia Cancer Specialists - Fairfax /ID# 265082 - Fairfax
Victoria
- St Vincent's Hospital Melbourne /ID# 261664 - Fitzroy Melbourne
Western Australia
- Sir Charles Gairdner Hospital /ID# 268579 - Nedlands
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 165 participants |
| Start Date | 2025-01-16 |
| Est. Completion | 2031-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06667687
The ClinicalTrials.gov registry entry for NCT06667687 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 165 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 219-participant average among 63 other Non-Hodgkin's Lymphoma trials with a reported enrollment target (25% lower). The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Hodgkin's Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which ABBV-291 is the first listed.
NCT06667687 reports 14 study locations spanning 13 distinct geographic areas - top geographies include Other, North Carolina, Oregon.
Frequently Asked Questions
What is clinical trial NCT06667687 about?
NCT06667687 is a clinical study titled "Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma". Non-Hodgkin's lymphoma (NHL) is a cancer that arises from the transformation of normal B and T lymphocytes (white blood cells). The purpose of this study is to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of ABBV-291 in adult participants in relapsed or refractory (R/R...
What is the current status of trial NCT06667687?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 165 participants. The study started on 2025-01-16. Estimated completion is 2031-11.
What conditions does trial NCT06667687 study?
This clinical trial studies the following conditions: Non-Hodgkin's Lymphoma.
What interventions are being tested in trial NCT06667687?
The interventions under investigation include: ABBV-291 (DRUG).
Who is sponsoring clinical trial NCT06667687?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06667687 being conducted?
This trial has 14 study locations across North Carolina, Oregon, Texas, Utah, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Hodgkin's Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
RECRUITING · Phase 1
-
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
RECRUITING · Phase 1
-
A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma
RECRUITING · Phase 1
-
T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
RECRUITING · Phase 1
-
Activated T Lymphocytes Expressing CARs, Relapsed CD19+ Malignancies Post-Allo HSCT(CARPASCIO)
ACTIVE NOT RECRUITING · Phase 1
-
High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.